Recent Updates
Recently added Catalysts

Sulfonylurea

Phase 3

Diabetes Mellitus, Type 2 | Small molecule | Metabolic |GSK plc|Last Updated: Mar 23, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment4,447

FDA Designations

No designations recorded

Clinical trial landscape

Sulfonylurea · 1 trial · 1 indication

Phase 3 1
NCT00379769RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in DiabetesDiabetes Mellitus, Type 2
COMPLETED4,447 Analytics
PHASE3COMPLETED
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
Diabetes Mellitus, Type 2Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events
Baseline through End of Study (up to 7.5 years)

The number of participants with cardiovascular death events (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation events (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) was recorded.

Independent Re-adjudication Outcome: Number of Participants Who Died Due to Any Cause
Baseline through End of Study (up to 7.5 years)

All deaths identified during the original record study and discovered after the re-adjudication efforts began were included.

Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint Definitions
Baseline through End of Study (up to 7.5 years)

IR was based on original RECORD endpoint definitions. CV death= no unequivocal non-CV cause (sudden death, death from acute vascular events, heart failure, acute MI, other CV causes, and deaths adjudicated as unknown cause). MI event=hospitalization + elevation of specific cardiac biomarkers above the upper limit of normal + cardiac ischemia symptoms/new pathological electrocardiogram findings. Stroke event=hospitalization + rapidly developed clinical signs of focal/global disturbance of cerebral function for more than 24 hours, with no apparent cause other than a vascular origin.

Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint Definitions
Baseline through End of Study (up to 7.5 years)

Independent re-adjudication was based on the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions. CV death included death resulting from an acute MI; sudden cardiac death and death due to heart failure, stroke, and to other CV causes. Deaths of unknown cause were counted as CV deaths. MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.

Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint Definitions
Baseline through End of Study (up to 7.5 years)

The number of participants with a CV death (or unknown) as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. CV death was defined as any death for which an unequivocal non-CV cause could not be established. CV death included death following heart failure, death following acute myocardial infarction (MI), sudden death, death due to acute vascular events, and other CV causes. Deaths due to unknown causes were classified as "unknown deaths," but were counted as CV deaths for the analysis of this endpoint.

Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions
Baseline through End of Study (up to 7.5 years)

The number of participants with a CV (or unknown) death as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. CV death included death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, and death due to other CV causes. Deaths of unknown cause were counted as CV deaths.

Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions
Baseline through End of Study (up to 7.5 years)

The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. An event of MI was defined as hospitalization plus elevation of cardiac biomarkers troponin (TN) I and/or TNT above the upper limit of normal (ULN) or creatinine kinase (CK) MB (M=muscle type; B=brain type) isoenzyme \>= 2x the ULN or CK \> 2x the ULN plus typical symptoms of cardiac ischemia or new pathological electrocardiogram findings, or cause of death adjudicated as MI.

Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions
Baseline through End of Study (up to 7.5 years)

The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia.

Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions
Baseline through End of Study (up to 7.5 years)

Par. with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. A stroke event=hospitalization plus rapidly developed clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours (unless interrupted by thrombolysis, surgery, or death), with no apparent cause other than a vascular origin, including par. presenting clinical signs/symptoms suggestive of subarachnoid haemorrhage/intracerebral haemorrhage/cerebral ischemic necrosis or cause of death adjudicated as stroke.

Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions
Baseline through End of Study (up to 7.5 years)

The number of participants with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.

Secondary Endpoints

Number of Participants With Cardiovascular Events and All-cause Deaths
Baseline through End of Study (up to 7.5 years)
Total Number of Cardiovascular Hospitalisations and Cardiovascular Deaths
Baseline through End of Study (up to 7.5 years)
Number of Participants With First Cardiovascular Hospitalisations/Cardiovascular Deaths by Stratum
Baseline through End of Study (up to 7.5 years)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
rosiglitazone in addition to background metforminEXPERIMENTALParticipants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
rosiglitazone in addition to background sulfonylureaEXPERIMENTALParticipants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
Sulfonylurea in addition to background metforminACTIVE_COMPARATORParticipants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.
Metformin in addition to background sulfonylureaACTIVE_COMPARATORParticipants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.

Interventions

NameTypeDescription
RosiglitazoneDRUGRosiglitazone maximum 8 mg per day
SulfonylureaDRUGSulfonylurea (SU) maximum permitted daily dose
MetforminDRUGMetformin maximum permitted daily dose .
Unlock Study Design Details

Eligibility Criteria

Age Range40 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites446

Inclusion Criteria: * Patients with type II diabetes mellitus as defined by 1999 World Health Organisation criteria. * Glycated haemoglobin (HbA1c) \>7.0 % to = 9.0 % at visit 1. * Use of an oral glucose lowering agent for a minimum of 6 months prior to screening and unchanged for 2 months prior to...

Countries:AustraliaBelgiumBulgariaCroatiaCzechiaDenmarkEstoniaFinlandFranceGermanyGreeceHungaryItalyLatviaLithuaniaNetherlandsNew ZealandPolandRomaniaRussiaSlovakiaSpainSwedenUkraineUnited Kingdom
Unlock Eligibility Criteria

Frequently asked questions about Sulfonylurea

What is Sulfonylurea used for?

Sulfonylurea is a small molecule being developed by GSK plc for the treatment of Type 2 Diabetes Mellitus. It is currently in Phase 3 clinical development as an investigational drug. The drug is being studied in the metabolic therapeutic area, with a focus on managing blood glucose levels in patients with this condition.

Who makes Sulfonylurea?

GSK plc, traded under the ticker GSK, is the developer of Sulfonylurea. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Type 2 Diabetes Mellitus. GSK is responsible for the ongoing research and development of this investigational small molecule.

What phase is Sulfonylurea in?

Sulfonylurea is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial, known as RECORD, has been completed and enrolled 4,447 participants with Type 2 Diabetes Mellitus.

What clinical trials is Sulfonylurea in?

Sulfonylurea has one completed Phase 3 clinical trial, identified as NCT00379769, titled 'RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes'. This trial enrolled 4,447 patients with Type 2 Diabetes Mellitus across multiple countries, including Australia, Belgium, and the United Kingdom.

Is Sulfonylurea FDA approved?

Sulfonylurea is not FDA approved. It is an investigational drug currently in Phase 3 clinical development. The completed Phase 3 trial, NCT00379769, has finished, but the drug has not yet received regulatory approval. Further development and regulatory review are required before it can be marketed.

Is Sulfonylurea the same as Rosiglitazone?

Sulfonylurea is not the same as Rosiglitazone. The Phase 3 trial NCT00379769, titled 'RECORD', evaluated Rosiglitazone for cardiac outcomes and regulation of glycaemia in diabetes. Sulfonylurea is a separate drug being developed by GSK, and the trial data provided does not indicate that these are the same compound.